文献速递中毒与环境急症

二甲基三硫醚在氰化物中毒吸入与注射模型中的疗效

DMTS is an effective treatment in both inhalation and injection models for cyanide poisoning using unanesthetized mice.
PubMed 文献 · Clin Toxicol (Phila) · 2017-09-19
一句话结论小鼠实验中,新型二甲基三硫醚制剂肌内注射对氰化氢吸入和氰化钾注射中毒均有保护作用。

本研究在未麻醉小鼠中评估新型二甲基三硫醚(DMTS)制剂对氰化物中毒的疗效,采用氰化氢(HCN)吸入模型(连续与非连续暴露)及氰化钾(KCN)皮下注射模型。DMTS经肌内注射给药。在KCN注射模型中,DMTS对3.73倍半数致死量(LD50)的KCN提供保护;在HCN吸入模型中,暴露于半数致死浓度(LC50)10分钟和40分钟的小鼠,DMTS治疗组存活率分别为87.5%和90.0%。两种致死性暴露模型中,DMTS治疗组小鼠的毒性体征也均有改善。

要点

  • 在KCN皮下注射模型中,DMTS肌内注射对3.73倍LD50剂量的KCN提供保护。
  • 在HCN吸入模型中,暴露于LC50剂量10分钟的小鼠,DMTS治疗组存活率为87.5%。
  • 在HCN吸入模型中,暴露于LC50剂量40分钟的小鼠,DMTS治疗组存活率为90.0%。
  • DMTS在连续和非连续HCN吸入暴露模型中均显示疗效。
  • 两种致死性暴露模型中,DMTS治疗组小鼠的毒性体征均有改善。

适用人群与场景

  • 未麻醉小鼠,用于氰化物中毒(HCN吸入或KCN皮下注射)的致死性暴露模型。

诊断标准与关键阈值

  • KCN注射模型:皮下注射3.73倍LD50剂量的KCN。
  • HCN吸入模型:暴露于LC50浓度的HCN,持续10分钟或40分钟。

处置流程与药物剂量

  • DMTS以肌内注射途径给药,用于未麻醉小鼠的氰化物中毒模型。

研究设计与关键结果

  • 研究类型:动物实验,使用未麻醉小鼠,比较DMTS治疗与对照在KCN注射和HCN吸入模型中的效果。
  • KCN注射模型:DMTS对3.73倍LD50剂量的KCN提供保护。
  • HCN吸入模型(10分钟LC50暴露):DMTS治疗组存活率87.5%。
  • HCN吸入模型(40分钟LC50暴露):DMTS治疗组存活率90.0%。
  • 两种致死性暴露模型中,DMTS治疗组小鼠的毒性体征均改善。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠),未麻醉。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Cyanide (CN) is a metabolic poison, halting ATP synthesis by inhibiting complex IV of the electron transport chain. If exposed at high enough concentrations, humans and most animals can die within minutes. Because time is a crucial factor in survival of CN poisoning, a rapidly bioavailable, nontoxic, easy to administer CN medical countermeasure could improve morbidity/mortality in a mass CN exposure scenario. The most likely route of exposure to CN is via inhalation.

OBJECTIVE: This study examined the efficacy of a new formulation for dimethyl trisulfide (DMTS), a countermeasure which has shown promise as a treatment for CN poisoning, using both inhalation and injection models of CN exposure.

METHODS: We developed a model of acute CN inhalation intoxication, using the highly toxic agent system from CH Technologies for nose-only exposure. Both continuous and discontinuous HCN exposure paradigms were implemented. For comparison, we also utilized a potassium cyanide (KCN) injection model. In all experiments, DMTS was administered as a cyanide countermeasure via intramuscular injection in unanesthetized mice.

RESULTS: We found DMTS administration to be highly protective against both subcutaneous KCN and HCN inhalation toxicity. In the KCN injection model, DMTS afforded protection against 3.73 times the LD50 dose of KCN. In our HCN inhalation exposure model, mice challenged with LC50 HCN doses for the duration of either 10- or 40-minute exposure paradigms demonstrated improved survival in the presence of DMTS treatment (87.5% and 90.0% survival, respectively). Animals in the DMTS treatment groups of both lethal exposure models similarly exhibited improvement in observed toxic signs.

CONCLUSION: We show that a newly developed formulation of DMTS is efficacious within two lethal CN exposure mouse models (inhalation and injection) and is highly effective by intramuscular injection. Within these HCN studies, we demonstrate efficacy of DMTS in both continuous and discontinuous inhalation exposure models.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. DeLeon SM, Downey JD, Hildenberger DM, et al. DMTS is an effective treatment in both inhalation and injection models for cyanide poisoning using unanesthetized mice. Clin Toxicol (Phila). 2017. PMID: 28922956. doi:10.1080/15563650.2017.1376749

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。